In a 24-month prospective study, Omni reduced intraocular eye pressure (IOP) by an average of 10.6 mmHg. A subgroup analysis found that Omni significantly reduced IOP for up to three years, regardless of lens status or disease severity.  

The device addresses all three known areas of outflow resistance through a single, clear corneal microincision without leaving an implant behind and is the first FDA-cleared minimally invasive glaucoma surgery (MIGS) device for circumferential canaloplasty in a single pass, the company said in a news release. 

The Omni Ultra features TruSync Plus technology, which provides enhanced control, precision and surgeon confidence of predictable viscodilation on advancement and retraction throughout the canaloplasty procedure, Sight Sciences said.